Slow Release Drug Conjugates for Local Eye Therapy for Diseases
- Detailed Technology Description
- University researchers have invented an approach to develop compounds the use of which would lessen the need for surgical placement and replacement of intravitreal implants for treating chronic vitreoretinal diseases. Frequent injections of therapies can lead to retinal detachment and endophthalmitis, and are extremely inconvenient to the patient. By developing a compound that has the property of being intravitreally injectable and long-acting, University researchers have come up with a way to administer therapy to the eye that does not require surgery or frequent injections. Animal studies have confirmed that the half-life of a therapeutic may be extended to between 8 to 20 weeks, or more.
- Supplementary Information
- Patent Number: US8017135B1
Application Number: US2004770885A
Inventor: Hostetler, Karl Y. | Freeman, William R. | Cheng, Lingyun
Priority Date: 31 Jan 2003
Priority Number: US8017135B1
Application Date: 2 Feb 2004
Publication Date: 13 Sep 2011
IPC Current: A61K000900
US Class: 424400 | 514110
Assignee Applicant: The Regents of the University of California
Title: Lipid-drug conjugates for local therapy of eye diseases
Usefulness: Lipid-drug conjugates for local therapy of eye diseases
Summary: The method is useful for treating: HSV-1 and CMV retinitis (claimed); and inappropriate proliferation of vascular tissues in the chamber of eye e.g. wet form of senile macular degeneration and diabetic proliferative retinopathy. Tests details are described but no results given.
Novelty: Treating herpes simplex virus-1 or cytomegalo virus retinitis comprises intravitreally injecting a suspension of 1-O-hexadecylcycloxypropyl-cyclic-cidofovir particles or hexadecyloxypropyl-3-phosphoganciclovir particles to the eye
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Other Disease
- Application No.
- 8017135
- Others
-
Tech ID/UC Case
19662/2003-113-0
Related Cases
2003-113-0
- *Abstract
-
None
- *IP Issue Date
- Sep 13, 2011
- *Principal Investigator
-
Name: Lingyun Cheng
Department:
Name: William Freeman
Department:
Name: Karl Hostetler
Department:
- Country/Region
- USA
For more information, please click Here
